Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
th ForreleaseonFebruary28 ,2017 NEWSRELEASE TheCanadianCancerSocietyandBrainCanadafundsixnewresearchprojects Montreal,February28th,2017.TheCanadianCancerSocietyandBrainCanada(withfinancialsupportfrom HealthCanadathroughtheCanadaBrainResearchFund)areproudtoannouncethefundingofsixnew multi-disciplinaryandmulti-institutionalresearchprojectsundertheCCS’Innovation,InnovationtoImpact andImpactgrantcompetitions.Thepartnerswillawardatotalofalmost$2.5Mtosixresearchteamsto supportinnovativeandcreativeproblemsolving,aswellassignificantprogression,inbrainandspinalcord cancerresearch. Based in Ontario and Saskatchewan, the six distinguished research teams totalling 20 researchers will developnewdiagnostictools,includingmoreeffectiveimagingtechniques,andnewtherapiesforbrainand spinalcordcancer. “The partnership between the Canadian Cancer Society and Brain Canada encourages collaboration between scientists from both the cancer and brain research fields. The projects selected through this program have the potential to advance our understanding of brain cancer, and ultimately improve the qualityoflifeandtreatmentofpeopleaffectedbybraincancer,”saidInezJabalpurwala,PresidentandCEO oftheBrainCanadaFoundation. “Thereisacriticalneedformoreresearchinbraincancer.Weareverygratefulforourpartnershipwith BrainCanada,aswellasourgenerousdonors,toenableCanadianscientiststomakesignificant contributionstoimprovingdiagnosisandtreatmentofbraincancer,”saidDr.MichaelWortzman, AssistantDirector,ResearchProgramsfromtheCanadianCancerSociety. BrainCanadafundsareprovidedthroughapublic-privatepartnershipwithHealthCanada,knownasthe CanadaBrainResearchFund. SixprojectsforbraincancerinCanada QuantitativeMRIasabiomarkeroftumourresistancetoradiationtreatmentinbrainmetastasis GregStanisz(SunnybrookHospital),ArjunSahgal,HanySolimanandKimDesmond(OdetteCancerCentre –SunnybrookHealthSciencesCentre,andHatefMehrabianandAngusLau(SunnybrookResearchInstitute) $441,000overthreeyears Cancerthathasspreadtothebraincanbetreatedwithtargetedhigh-doseradiation.However,itisdifficult totellearlyonifthetumourisrespondingtotherapy.WiththesupportofanInnovationGrant,Dr.Greg Stanisz’teamshowedthatnewmedicalresonanceimaging(MRI)techniquescoulddetecttumourresponse asearlyasoneweekaftertreatment.TheteamwillnowextendtheseMRIstudiestodifferentiatebetween tumour progression and radiation side effects, which can look similar in medical scans but require very differenttreatments.Thesenewtechniquesmayhelpdoctorsadjustandimprovetreatmentplans. 1 Thefeasibilityofhyperpolarized13C-PyruvateMRIformonitoringpatientswithintracranialmetastasis Charles Cunningham (Sunnybrook Research Institute), Arjun Saghal and Hany Soliman (Odette Cancer Centre–SunnybrookHealthSciencesCentre),andMichaelChan(SunnybrookHealthSciencesCentre) $187,915overthreeyears Surgeryandradiationarestandardtreatmentsforcancerthathasspreadtothebrain.Recentresearchhas revealedthatcancercellswithhighlevelsofthechemicallactateareaggressiveandresistradiationtherapy. Dr.CharlesCunningham’steamwillstudywhetheranenhancedimagingmethodthatcandetectlactate can help predict how cancer in the brain will behave. They will compare it to other routine imaging techniquesusedtoassesspeopleaffectedbybraincancerbeforebrainradiationtherapy.Thisnewmethod mayhelptailortreatmentplanstoprolongsurvival. Integrativediscoveryofionchannelsasdrugtargetsinglioblastoma JüriReimand(OntarioInstituteforCancerResearch)andXiHuang(SickKidsResearchInstitute) $196,000overtwoyears Manydifferentdiseasesaretreatedwithdrugsthatactontunnelsthatpassthroughthecell’ssurfaceand allowittogenerateelectricalsignals.Sofar,thesechannelshavenotbeenthetargetofcancerdrugs.Dr. JüriReimand’steamwillidentifywhichchannelsareabnormalincancerandcanbetargetedwithdrugs currentlyusedtotreatotherdiseases.Theywillthenstudytheroleofthesechannelsinglioblastoma–an aggressive form of brain cancer – and test promising drugs in the lab. This could rapidly lead to new therapeuticoptionsforhardtotreatbraincancer. MolecularcharacterizationoftranscriptionalrepressorcapicuainGBM KennethAldapeandSeveraBunda(PrincessMargaretCancerCentre–UHN) $196,000overtwoyears The capicua (CIC) protein acts as a brake on cell growth in normal cells. This brake is often lost in glioblastoma,anaggressiveformofbraincancer,butlittleelseisknownaboutitsroleincancer.Dr.Kenneth Aldape’steamwillstudytheimpactofCIClossinglioblastomaandwhetherthiscancauseresistanceto therapiesthathavesofarhaddisappointingresultsinpeopleaffectedbybraincancer.Understandingthese newaspectsofbraincancerbiologywillhelpresearchersdevelopnewtreatmentsforthesehardtotreat tumours. Using synthetic antibody parts to construct antibody-based imaging devices – anti-EGFR molecular targetedimagingprobesfordiagnosingandmonitoringglioblastoma Clarence Geyer and Humphrey Fonge (University of Saskatchewan), and Vijayananda Kundapur (SaskatchewanCancerAgency–SaskatoonCancerCentre) $195,968overtwoyears Diagnostic features of glioblastoma, an aggressive form of brain cancer, are difficult to visualize using standardmedicalimagingtechniques.GiventhatglioblastomacellsdisplayhighlevelsoftheEGFRprotein ontheirsurface,Dr.ClarenceGeyer’steamwillgeneratenewimagingmoleculesthatcandetectEGFRin glioblastomaanddisplayitonapositronemissiontomography(PET)scan.Theseimagingtoolscouldbe usedtoimproveglioblastomadetectionanddiagnosisandtoguidesurgery. 2 Advancingbiologybasedtherapiesforrhabdoidbraintumours AnnieHuang,JamesRutkaandEricBouffet(TheHospitalforSickChildren),CherylArrowsmith(University ofToronto),andDanielDeCarvalho(PrincessMargaretCancerCentre-UHN) $1,214,047overfiveyears Rhabdoidbraintumoursarethemostcommonbraincancersininfants.Usuallytheseaggressivetumours aretreatedwithintensechemotherapyandradiationtherapy,whichcanhaveserioussideeffects.Dr.Annie Huang’s team found that these brain tumours come in 2 forms, including one that can be cured using chemotherapyalone.Herteamwillnowdevelopatesttodistinguishbetweenthe2forms.Shewillalso determinewhichdrugsarethemosteffectiveagainsteachformofthecancerinthelab.Thiswillformthe foundationforaclinicaltrialofpersonalizedtreatments. AbouttheCanadianCancerSociety TheCanadianCancerSocietyisthelargestnationalcharitablefunderofcancerresearchinCanada.Thanks toourgenerousdonorsandourrigorous,gold-standardpeer-reviewprocess,wearefundinghundredsof researchersinuniversities,hospitalsandresearchcentresacrossCanada.TheSocietyhasthemostimpact, againstthemostcancers,inthemostcommunitiesinCanada.Togetherwearediscoveringnewwaysto change cancer forever. For more information, visit www.cancer.ca or call our toll-free bilingual Cancer InformationServiceat1-888-939-3333(TTY1-866-786-3934). AboutBrainCanadaandtheCanadaBrainResearchFund BrainCanadaisanationalnon-profitorganizationheadquarteredinMontreal,Quebec,thatenablesand supports transformative, original and outstanding brain research in Canada. For more than one decade, BrainCanadahasmadethecaseforthebrainasasingle,complexsystemwithcommonalitiesacrossthe rangeofneurologicaldisorders,mentalillnessesandaddictions,brainandspinalcordinjuries.Lookingat the brain as one system has underscored the need for increased collaboration across disciplines and institutions, and a smarter way to invest in brain research that is focused on outcomes that will benefit peoplewithlivedexperienceandfamilies.BrainCanada’svisionistounderstandthebrain,inhealthand illness,toimprovelivesandachievesocietalimpact. TheCanadaBrainResearchFundisapublic-privatepartnershipestablishedbetweenBrainCanadaand HealthCanadatoencourageCanadianstoincreasetheirsupportofbrainresearch,andmaximizethe impactandefficiencyofthoseinvestments.BrainCanadaisraising$120millionfromprivateandnonfederalsources,whichisbeingmatchedbytheGovernmentofCanadaona1:1basis.TheFundsupports “the very best Canadian neuroscience, fostering collaborative research and accelerating the pace of discovery,inordertoimprovethehealthandqualityoflifeofCanadianswhosufferfrombraindisorders.” Formoreinformation:www.braincanada.ca. TheviewsexpressedhereindonotnecessarilyrepresenttheviewsofHealthCanada. Source: RosieHales CommunicationsSpecialist CanadianCancerSociety Tel.:(416)934-5338 [email protected] www.cancer.ca KatarinaStojkovic CommunicationsOfficer BrainCanadaFoundation Tel.:(514)989-2989,ext.110 [email protected] www.braincanada.ca 3